Enhanced antigen presentation on the tumor cells by EZH2 inhibitors or CRISPR-mediated EZH2 deficiency have been shown to increase antigen-specific CD8+ T-cell proliferation, IFN-γ production, and tumor cell cytotoxicity [151]. The gene discussed is CD8A; the disease is neoplasm.